limited and unsatisfactory treatment options currently available for
patients with genotype 4 hepatitis C virus (HCV), the results from the
COMMAND-4 study presented at IDWeek 2014 offer some promise for these
In the study, 82 patients with genotype 4 HCV were treated with 60 mg
once daily of the NS5A inhibitor daclatasvir in combination with
peginterferon alfa 180 µg once weekly and weight-based ribavirin
(1000-1200 mg/day) twice daily. In the study’s other arm, 42 patients
received placebo plus peginterferon alfa and ribavirin.
Researchers evaluated the safety and efficacy of this combination in
treatment-naïve patients with genotype 4 HCV, including patients with
cirrhosis. The primary endpoint of the study was sustained virologic
response at 12 weeks (SVR12).
- See more at: http://www.hcplive.com/conferences/idweek/Combination-Treatment-with-Daclatasvir-Produces-Good-Results-in-Patients-with-Genotype-4-Hepatitis-C#sthash.wH70EOnK.dpuf
Labels: COMMAND-4, daclatasvir + PEG/R, genotype 4, GT4, IDWeek 2014